{"help":"Return the metadata of a dataset (package) and its resources. :param id: the id or name of the dataset :type id: string","success":true,"result":[{"id":"35a4418f-3ddc-45e1-b7c4-c6f74080c31f","name":"long-term-changes-gut-microbiota-antibiotic-resistance-and-metabolic-parameters-after","title":"Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial","maintainer":"\u53f0\u7063\u4eba\u9ad4\u5fae\u751f\u7269\u76f8\u8cc7\u6599\u5eab","maintainer_email":"summerhill001@gmail.com","notes":"\u003Cp\u003EBackground: In first-line treatment of Helicobacter pylori, we have previously shown that the eradication frequency was 83\u00b77% (95% CI 80\u00b74-86\u00b76) for triple therapy for 14 days (T14; lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily), 85\u00b79% (82\u00b77-88\u00b76) for concomitant therapy for 10 days (C10; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily), and 90\u00b74% (87\u00b76-92\u00b76) for bismuth quadruple therapy for 10 days (BQ10; bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day). In this follow-up study, we assess short-term and long-term effects of these therapies on the gut microbiota, antibiotic resistance, and metabolic parameters.\u003C\/p\u003E\n\u003Cp\u003EMethods: This was a multicentre, open-label, randomised trial done at nine medical centres in Taiwan. Adult patients (\u0026gt;20 years) with documented H pylori infection were randomly assigned (1:1:1, with block sizes of six) to receive T14, C10, or BQ10. We assessed long-term outcomes (reinfection frequency, changes in the gut microbiota, antibiotic resistance, and metabolic parameters) in patients with available data, excluding all protocol violators and those with unknown post-treatment H pylori status. Faecal samples were collected before treatment and 2 weeks, 2 months, and at least 1 year after eradication therapy. Amplification of the V3 and V4 hypervariable regions of the 16S rRNA was done followed by high-throughput sequencing. Susceptibility testing for faecal Escherichia coli and Klebsiella pneumoniae was done. This trial is complete and registered with ClinicalTrials.gov, NCT01906879.\u003C\/p\u003E\n\u003Cp\u003EFindings: Between July 17, 2013, and April 20, 2016, 1620 participants were randomly assigned to the three treatment groups (540 [33%] per group). 1214 (75%) attended 1-year follow-up and are included in this analysis. Compared with baseline, alpha diversity was significantly reduced 2 weeks after T14 (p=0\u00b70002), C10 (p\u0026lt;0\u00b70001), and BQ10 (p\u0026lt;0\u00b70001) treatment. Beta diversity was also significantly altered 2 weeks after T14 (p=0\u00b70010), C10 (p=0\u00b70001), and BQ10 (p=0\u00b70001). Alpha diversity and beta diversity were restored at week 8 (p=0\u00b714 and p=0\u00b7918, respectively) and 1 year (p=0\u00b714 and p=0\u00b7918) after T14, but were not fully recovered at week 8 and after 1 year in patients treated with C10 (p=0\u00b70001 and p=0\u00b7013 at week 8; p=0\u00b7019 and p=0\u00b7064 at 1 year) and BQ10 (p\u0026lt;0\u00b70001 and p=0\u00b70002; p=0\u00b7001 and p=0\u00b7029). A transient increase at week 2 after T14 and C10 of the resistance rates of E coli to ampicillin-sulbactam (12% [15\/127] to 66% [38\/58] for T14, 7% [10\/135] to 64% [28\/44] for C10), cefazolin (13% [16\/127] to 43% [25\/58] for T14, 10% [13\/135] to 41% [18\/44] for C10), cefmetazole (8% [10\/127] to 26% [15\/58] for T14, 4% [5\/135] to 18% [8\/44] for C10), levofloxacin (8% [10\/127] to 35% [20\/58] for T14, 7% [10\/135] to 32% [14\/44] for C10), gentamicin (13% [19\/146] to 47% [27\/58] for T14, 15% [22\/149] to 45% [20\/44] for C10), and trimethoprim-sulfamethoxazole (33% [48\/146] to 86% [50\/58] for T14, 28% [42\/148] to 86% [38\/44] for C10; p\u0026lt;0\u00b705 in paired samples in the above analyses) returned to basal state at week 8 and after 1 year. Although bodyweight and body-mass index slightly increased, there were significant improvements in metabolic parameters, with a decrease in insulin resistance, triglycerides, and LDL and an increase in HDL. Overall, there was no significant change in the prevalence of metabolic syndrome at week 8 and 1 year after T14, C10, and BQ10.\u003C\/p\u003E\n\u003Cp\u003EInterpretation: Eradication of H pylori infection has minimal disruption of the microbiota, no effect on antibiotic resistance of E coli, and some positive effects on metabolic parameters. Collectively, these results lend support to the long-term safety of H pylori eradication therapy.\u003C\/p\u003E\n","url":"https:\/\/www.hmp.org.tw\/?q=dataset\/long-term-changes-gut-microbiota-antibiotic-resistance-and-metabolic-parameters-after","state":"Active","private":true,"revision_timestamp":"Thu, 10\/29\/2020 - 02:51","metadata_created":"Thu, 10\/29\/2020 - 02:51","metadata_modified":"Thu, 10\/29\/2020 - 02:51","creator_user_id":"82398fd6-ac0a-446a-a9c0-ab9d797f47f0","type":"Dataset","tags":[{"id":"f4f493fd-0878-4fd0-90e1-78e6c8e1c4e7","vocabulary_id":"2","name":"Gut microbiota"}],"groups":[{"description":"\u003Cp\u003E\u4ee5\u553e\u6db2\u3001\u7cde\u4fbf\u3001\u53ca\u764c\u75c7\u7d44\u7e54\u4e4b\u5fae\u83cc\u53e2\u76f8\u4f5c\u70ba\u8a3a\u65b7\u80f0\u81df\u764c\u3001\u9810\u6e2c\u6574\u9ad4\u5b58\u6d3b\u7387\u3001\u53ca\u8abf\u63a7\u6cbb\u7642\u53cd\u61c9\u4e4b\u816b\u7624\u751f\u7269\u6a19\u8a18\u003C\/p\u003E\n","id":"7a5dddf3-4503-464e-865c-c44ccd9cd1e7","image_display_url":"https:\/\/www.hmp.org.tw\/sites\/default\/files\/cmu.jpg","title":"(11) \u4e2d\u570b\u91ab\u85e5\u5927\u5b78\u9644\u8a2d\u91ab\u9662\u6d88\u5316\u91ab\u5b78\u4e2d\u5fc3 - \u6797\u8087\u5802\u91ab\u5e2b\u5718\u968a","name":"group\/11-\u4e2d\u570b\u91ab\u85e5\u5927\u5b78\u9644\u8a2d\u91ab\u9662\u6d88\u5316\u91ab\u5b78\u4e2d\u5fc3-\u6797\u8087\u5802\u91ab\u5e2b\u5718\u968a"}]}]}